Trial Profile
A Phase II Study of Interleukin-21 (IL-21) in Patients With Metastatic or Recurrent Malignant Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Denenicokin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 07 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 07 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned end date changed from 17 Aug 2009 to 1 Jun 2012 as reported by ClinicalTrials.gov.